CERTIFICATE OF ANALYSIS Technoview Rivaroxaban CON H



Attachment 22

DQ0300.03

TF0326.07

3321C02.02

REF

5090174-RUO

LOT

3321C02.02

8

2026-06-30

| Analytical Procedures | | Requirement | Result | |
|-----------------------|---|--|-------------|----|
| | Cap color | red | confirmed | OK |
| visual inspection | Vial type | clear glass vial | confirmed | OK |
| | Vial label | according to packaging SOP | confirmed | OK |
| | Vial barcode | according to packaging SOP | confirmed | OK |
| | Box label | according to packaging SOP | confirmed | OK |
| | Box barcode | according to packaging SOP | confirmed | ОК |
| | Package insert | present | confirmed | ОК |
| | Batch table | present | confirmed | OK |
| | Appearance before reconstitution | buff colored plug of lyophilized material | confirmed | OK |
| | Appearance after reconstitution | amber colored liquid | confirmed | ОК |
| Virology | HBsAg / HBsAg | Negative | Negative | ок |
| | HIV-Ak / HIV-Ab | Negative | Negative | |
| | HCV-AK / HCV-Ab | Negative | Negative | |
| The testing methods a | applied were FDA-approved or CE marked. | | | |
| Recovery of control | | 226.1 - 376.8 ng/mL | 313.4 ng/mL | OF |

Prepared by

Lukas GRUBELNIG &

1 5. JULI 2025

Date

Approved by

16. JULI 2025

Date